Cardeon's 2024 saw improved operating results, a major portfolio write-down, and new capital raised, while the listed portfolio underperformed the market. Management remains optimistic about long-term value creation in life science and medtech.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.